Stock Rich List
#6365 on the rich list of 14,644 insiders

Beth C. Seidenberg

Director at Progyny; Director at Latigo Biotherapeutics; Director at Kyverna Therapeutics. Based in Thousand Oaks, California.

$15.2M
in disclosed stock, −$115K (−0.75%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
6365th of 14,644
Companies held
5
Largest holding
PGNY, 67.1% of total
Latest SEC filing
Aug 10, 2026
Listed but not counted
$394M

What the $15.2M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Progyny PGNY
Common Stock
Indirectly (see filing footnote)227,906$35.45$8.1M53.0%Form 4, May 23, 2024
Vera Therapeutics VERA
Class A Common Stock
Directly131,553$26.75$3.5M23.1%Form 4, Oct 28, 2024
Progyny PGNY
Common Stock
Directly43,416$35.45$1.5M10.1%Form 4, May 23, 2024
Sagimet Biosciences SGMT
Series A Common Stock
Directly84,768$9.62$815K5.3%Form 4, Jul 18, 2023
Progyny PGNY
Common Stock
Indirectly (see filing footnote)17,162$35.45$608K4.0%Form 4, Jun 9, 2023
Sagimet Biosciences SGMT
Series A Common Stock
Indirectly (see filing footnote)46,875$9.62$451K3.0%Form 4, Jul 18, 2023
Vera Therapeutics VERA
Class A Common Stock
Through Samuel B. Seidenberg Irrevocable Trust4,012$26.75$107K0.7%Form 4, Oct 28, 2024
Kyverna Therapeutics KYTX
Common Stock
Directly21,727$4.37$95K0.6%Form 4, May 27, 2026
Atara Biotherapeutics ATRA
Common Stock
Directly4,628
split-adjusted
$6.34$29K0.2%Form 4, May 31, 2023
Atara Biotherapeutics ATRA
Common Stock
Through Samuel B. Seidenberg Irrevocable Trust8
split-adjusted
$6.34$500.0%Form 4, May 31, 2023

Share counts are the amounts Beth C. Seidenberg reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Beth C. Seidenberg's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Progyny PGNY
Common Stock
Through KPCB XIII Associates, LLC
Held by a company or fund the insider manages
5,074,615$35.45$180M—Form 4, May 23, 2024
Latigo Biotherapeutics LTGO
Common Stock
Through Westlake BioPartners Fund I, L.P.
Held by a company or fund the insider manages
5,944,009$13.24$78.7M—Form 4, Aug 10, 2026
Latigo Biotherapeutics LTGO
Common Stock
Through Westlake BioPartners Fund II, L.P.
Held by a company or fund the insider manages
5,160,847$13.24$68.3M—Form 4, Aug 10, 2026
Latigo Biotherapeutics LTGO
Common Stock
Through Westlake BioPartners Opportunity Fund I, L.P.
Held by a company or fund the insider manages
2,094,813$13.24$27.7M—Form 4, Aug 10, 2026
Sagimet Biosciences SGMT
Series A Common Stock
Through KPCB PBD Associates, LLC
Held by a company or fund the insider manages
1,899,475$9.62$18.3M—Form 4, Jul 18, 2023
Kyverna Therapeutics KYTX
Common Stock
Through Westlake BioPartners Fund I, L.P.
Held by a company or fund the insider manages
3,787,940$4.37$16.6M—Form 4, May 27, 2026
Kyverna Therapeutics KYTX
Common Stock
Through Westlake BioPartners Opportunity Fund I, L.P.
Held by a company or fund the insider manages
869,317$4.37$3.8M—Form 4, May 27, 2026
Atara Biotherapeutics ATRA
Common Stock
Through KPCB XV Associates, LLC
Held by a company or fund the insider manages
72,889
split-adjusted
$6.34$462K—Form 4, May 31, 2023
Atara Biotherapeutics ATRA
Common Stock
Through KPCB XV Founders Fund, LLC
Held by a company or fund the insider manages
2,177
split-adjusted
$6.34$14K—Form 4, May 31, 2023

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Dec 18, 2025BoughtKYTX133,333$7.50$1000KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
6362Dale W. Boyles
CHIEF FINANCIAL OFFICER, Warrior Met Coal. Dallas, TX
$15.2M−$5K (−0.03%)
6363Kevin B. Habicht
EVP, Chief Financial Officer, NNN REIT. Orange, FL
$15.2M−$136K (−0.89%)
6364Van A. Dukeman
President and CEO, First Busey. Leawood, KS
$15.2M−$265K (−1.71%)
6365Beth C. Seidenberg
Director, Progyny. Thousand Oaks, CA
$15.2M−$115K (−0.75%)
6366Murray R. Garnick
EVP & General Counsel, Altria Group. Richmond, VA
$15.2M−$322K (−2.07%)
6367Michael Larry Snider
President and COO, LGI Homes. The Woodlands, TX
$15.2M−$768K (−4.80%)
6368Fred E. Cohen
Director, Kyverna Therapeutics. Brisbane, CA
$15.2M−$291K (−1.87%)

Other Progyny insiders

All PGNY insiders

Questions

How much stock does Beth C. Seidenberg own?

Beth C. Seidenberg holds $15,243,863 in listed stock based on SEC filings and current prices, mostly Progyny (PGNY). That ranks 6365th on the Stock Rich List.

Is this Beth C. Seidenberg's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Beth C. Seidenberg last buy or sell stock?

The most recent open-market trade on file is a purchase of 133,333 KYTX shares on Dec 18, 2025 at $7.50.